GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Molecule to Treat Various Risk Factors of Cardiometabolic Disease Goes into Clinic

  • Genfit reports the entry into Phase I trials of GFT505, the company’s molecule for the simultaneous treatment of several risk factors of cardiometabolic disease.

    According to a Genfit spokesperson, GFT505, a multimodal, pluripotent compound, acts on the molecular level by activating PPAR (peroxisome proliferator-activated receptors) nuclear receptors, which play a central role in the regulation of lipid metabolism and the control of glycemia.

    “With a completely original profile—Pan-sPPARm, selective PPAR modulator, with a preferential action on the PPAR alpha family—and evaluated by Genfit’s proprietary SNuRM technology platform, GFT505 targets a wide range of indications: mixed dyslipidemia, type II diabetes, and atherosclerosis,” explains Dean Hum, vp and CSO.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?